Esophageal Cancer

June 2nd 2024

The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.

March 14th 2024

Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.

January 24th 2024

Investigators note that early interventions such as nutritional support and prehabilitation require further investigation to increase both the quality of life and overall survival for patients with esophageal cancer.

January 20th 2024

Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.